SCHEMBL6512111

SCHEMBL6512111

COC(=O)[C@H](CC(C)C)Nc1nc(Nc2cccc(F)c2)cc(Sc2ccc(OC)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDR P35968 1/20 0.37
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
GALR2 O43603 2/20 0.36
MAPT P10636 3/20 0.36
TAS1R3 Q7RTX0 3/20 0.36
TAS1R1 Q7RTX1 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
GALR1 P47211 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512117 1.00 CTSK (0.38) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6512168 0.93 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL8299305 0.93 CTSK (0.38) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6512174 0.93 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513215 0.91 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513221 0.91 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6506223 0.89 CTSK (0.42) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513831 0.89 CTSK (0.44) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6510461 0.89 ALDH1A1 (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6510466 0.89 ALDH1A1 (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed